2. Academic Validation
  3. BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy

BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy

  • Mol Metab. 2022 Dec:66:101633. doi: 10.1016/j.molmet.2022.101633.
Tina Zimmermann 1,  Leo Thomas 2,  Tamara Baader-Pagler 3,  Peter Haebel 4,  Eric Simon 5,  Wolfgang Reindl 6,  Besnik Bajrami 7,  Wolfgang Rist 8,  Ingo Uphues 9,  Daniel J Drucker 10,  Holger Klein 11,  Rakesh Santhanam 12,  Dieter Hamprecht 13,  Heike Neubauer 14,  Robert Augustin 15
Affiliations

Affiliations

  • 1 Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Str. 65, 88400 Biberach an der Riβ, Germany. Electronic address: tina.zimmermann@boehringer-ingelheim.com.
  • 2 Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Str. 65, 88400 Biberach an der Riβ, Germany. Electronic address: leo.thomas@boehringer-ingelheim.com.
  • 3 Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Str. 65, 88400 Biberach an der Riβ, Germany. Electronic address: tamara.baader-pagler@boehringer-ingelheim.com.
  • 4 Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Str. 65, 88400 Biberach an der Riβ, Germany. Electronic address: peter.haebel@boehringer-ingelheim.com.
  • 5 Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Str. 65, 88400 Biberach an der Riβ, Germany. Electronic address: eric.simon@boehringer-ingelheim.com.
  • 6 Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Str. 65, 88400 Biberach an der Riβ, Germany. Electronic address: wolfgang.reindl@boehringer-ingelheim.com.
  • 7 Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Str. 65, 88400 Biberach an der Riβ, Germany. Electronic address: besnik.bajrami@boehringer-ingelheim.com.
  • 8 Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Str. 65, 88400 Biberach an der Riβ, Germany. Electronic address: wolfgang.rist@boehringer-ingelheim.com.
  • 9 Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Str. 65, 88400 Biberach an der Riβ, Germany. Electronic address: ingo.uphues@boehringer-ingelheim.com.
  • 10 Lunenfeld-Tanenbaum Research Institute, University of Toronto, Mount Sinai Hospital, 600 University Avenue, Toronto, Ontario M5G 1X5, Canada. Electronic address: drucker@lunenfeld.ca.
  • 11 Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Str. 65, 88400 Biberach an der Riβ, Germany. Electronic address: holger.klein@boehringer-ingelheim.com.
  • 12 Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Str. 65, 88400 Biberach an der Riβ, Germany. Electronic address: rakesh.santhanam@boehringer-ingelheim.com.
  • 13 Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Str. 65, 88400 Biberach an der Riβ, Germany; Boehringer Ingelheim Research Italia, Via Lorenzini 8, 20139 Milano, Italy. Electronic address: Dieter.Hamprecht@pharmaxis.com.au.
  • 14 Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Str. 65, 88400 Biberach an der Riβ, Germany. Electronic address: heike.neubauer@boehringer-ingelheim.com.
  • 15 Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Str. 65, 88400 Biberach an der Riβ, Germany. Electronic address: Robert.augustin@boehringer-ingelheim.com.
PMID: 36356832 DOI: 10.1016/j.molmet.2022.101633
Abstract

Objective: Obesity and its associated comorbidities represent a global health challenge with a need for well-tolerated, effective, and mechanistically diverse pharmaceutical interventions. Oxyntomodulin is a gut peptide that activates the Glucagon Receptor (GCGR) and glucagon-like peptide-1 receptor (GLP-1R) and reduces bodyweight by increasing energy expenditure and reducing energy intake in humans. Here we describe the pharmacological profile of the novel Glucagon Receptor (GCGR)/GLP-1 Receptor (GLP-1R) dual agonist BI 456906.

Methods: BI 456906 was characterized using cell-based in vitro assays to determine functional agonism. In vivo pharmacological studies were performed using acute and subchronic dosing regimens to demonstrate target engagement for the GCGR and GLP-1R, and weight lowering efficacy.

Results: BI 456906 is a potent, acylated peptide containing a C18 fatty acid as a half-life extending principle to support once-weekly dosing in humans. Pharmacological doses of BI 456906 provided greater bodyweight reductions in mice compared with maximally effective doses of the GLP-1R agonist semaglutide. BI 456906's superior efficacy is the consequence of increased energy expenditure and reduced food intake. Engagement of both receptors in vivo was demonstrated via glucose tolerance, food intake, and gastric emptying tests for the GLP-1R, and liver nicotinamide N-methyltransferase mRNA expression and circulating biomarkers (Amino acids, fibroblast growth factor-21) for the GCGR. The dual activity of BI 456906 at the GLP-1R and GCGR was supported using GLP-1R knockout and transgenic reporter mice, and an ex vivo bioactivity assay.

Conclusions: BI 456906 is a potent GCGR/GLP-1R dual agonist with robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake.

Keywords

G protein coupled receptor; Glucagon; Glucagon-like peptide-1; Obesity; Peptide.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z